Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2014

View Archived Issues

Morphine tolerance reversed by blocking neuropeptide FF2 receptor

MYL3 gene mutation identified in hypertrophic cardiomyopathy pedigree

SomaGenics receives NIH funding to develop RNA technologies

Valneva begins phase II trial of VLA-84

Chimerix and ContraVir establish strategic collaboration for CMX-157

Merck & Co. expands oncology portfolio with acquisition of OncoEthix

Inovio Pharmaceuticals begins DNA immunotherapy trial for breast, lung and pancreatic cancer

Curis initiates phase I trial of CUDC-907 in patients with solid tumors

GlaxoSmithKline varicella zoster vaccine reduces incidence of shingles in phase III trial

Fate Therapeutics reports interim data from phase II trial of Prohema

Phase II trial of IPH-2201 begins in squamous cell carcinoma of the oral cavity

SciClone to commercialize clevidipine and bivalirudin in China

IND submitted for phase II study of NS2 for noninfectious anterior uveitis

Immunogenicity and safety of the Ebola virus vaccine cAd3-EBO in a phase I trial

University of Leicester patent describes compounds for bacterial infections

Xencor and Novo Nordisk form collaboration using Xencor's XmAb technologies

Marina Biotech and MiNA Therapeutics form agreement for saRNA-based therapeutics

Roche to acquire Dutalys

FDA approves AbbVie's Viekira Pak for chronic genotype 1 HCV infection

NETRIS Pharma creates first humanized monoclonal antibody against netrin-1

Bayer Schering Pharma describes novel thrombin inhibitors

Temple University prepares and tests novel glutamate uptake modulators

K(Ca)3.1 channel activators reported in Astellas Pharma patent

Xiapex receives positive opinion by CHMP for Peyronie's disease

Baxter applies for FDA approval of BAX-111 for Von Willebrand disease

First U.S. approval granted for nivolumab injection for metastatic melanoma

European marketing approval granted to Clinuvel's Scenesse

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...